164 related articles for article (PubMed ID: 32420699)
1. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Chinen Y; Tanba K; Kuwahara-Ota S; Fujibayashi Y; Nishiyama D; Isa R; Yamaguchi J; Kawaji-Kanayama Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
Cancer Med; 2020 Jul; 9(14):5185-5199. PubMed ID: 32420699
[TBL] [Abstract][Full Text] [Related]
2. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
[TBL] [Abstract][Full Text] [Related]
4. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
[TBL] [Abstract][Full Text] [Related]
5. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
[TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
8. Novel wiring of the AKT-RSK2 signaling pathway plays an essential role in cancer cell proliferation via a G
Choi JS; Cho YY
Biochem Biophys Res Commun; 2023 Jan; 642():66-74. PubMed ID: 36566564
[TBL] [Abstract][Full Text] [Related]
9. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
11. p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta.
Doehn U; Gammeltoft S; Shen SH; Jensen CJ
Biochem J; 2004 Sep; 382(Pt 2):425-31. PubMed ID: 15206906
[TBL] [Abstract][Full Text] [Related]
12. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.
Frödin M; Jensen CJ; Merienne K; Gammeltoft S
EMBO J; 2000 Jun; 19(12):2924-34. PubMed ID: 10856237
[TBL] [Abstract][Full Text] [Related]
13. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
14. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
15. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
16. BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.
Tsukamoto T; Nakahata S; Sato R; Kanai A; Nakano M; Chinen Y; Maegawa-Matsui S; Matsumura-Kimoto Y; Takimoto-Shimomura T; Mizuno Y; Kuwahara-Ota S; Kawaji Y; Taniwaki M; Inaba T; Tashiro K; Morishita K; Kuroda J
Cancer Genomics Proteomics; 2020; 17(1):77-89. PubMed ID: 31882553
[TBL] [Abstract][Full Text] [Related]
17. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
[TBL] [Abstract][Full Text] [Related]
19. Ribosomal S6 Kinase 2 (RSK2) maintains genomic stability by activating the Atm/p53-dependent DNA damage pathway.
Lim HC; Xie L; Zhang W; Li R; Chen ZC; Wu GZ; Cui SS; Tan EK; Zeng L
PLoS One; 2013; 8(9):e74334. PubMed ID: 24086335
[TBL] [Abstract][Full Text] [Related]
20. PI3K signaling mediates diverse regulation of ATF4 expression for the survival of HK-2 cells exposed to cadmium.
Fujiki K; Inamura H; Matsuoka M
Arch Toxicol; 2014 Feb; 88(2):403-14. PubMed ID: 24057571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
